Park S. Bramhall Counsel

New York
T 646.414.6925 | F 973.535.3115



With an emphasis on life sciences, Park focuses his practice on mergers and acquisitions, private equity and venture capital transactions, registered offerings and private placements, and corporate and securities law.

Clients value Park for his sophisticated knowledge of the legal issues facing businesses in the science and technology industries. He has advised companies and their boards on a wide range of issues, including transactions, SEC compliance and disclosure issues, and corporate governance matters. His experience in the health care sector extends back to his early work as a financial analyst at Health First Inc., a nonprofit managed care organization.

In addition to his law degree, Park also earned a Master of Public Affairs from Princeton University’s Woodrow Wilson School of Public and International Affairs, and served as Special Assistant to the Chief of Staff of the U.S. Immigration and Naturalization Service.

Publications

Nasdaq Solicits Comments on Shareholder Approval Rules for Private Placements
Capital Markets & Securities Client Alert, June 21, 2017
Park Bramhall
Senate Introduces Bill to Increase Oversight of Activist Investors
Capital Markets & Securities and Investment Management Client Alert, April 5, 2016
Park Bramhall
House Passes Bill to Expand Accredited Investor Definition
Capital Markets & Securities Group Client Alert, February 9, 2016
Park Bramhall
View More...

Press Mentions

Lowenstein Sandler represented Pernix Therapeutics Holdings Inc. in its acquisition of the Zohydro® ER Franchise from Zogenix Inc. Under terms of the agreement, Pernix, through its wholly-owned subsidiary, Ferrimill Limited, paid Zogenix $70 million in cash, issued to Zogenix 1,682,086 shares of Pernix common stock and deposited an additional $10 million in cash in escrow to fund potential indemnification claims for a period of 12 months following the closing. Pernix also purchased certain Zohydro ER inventory. The Lowenstein deal team is led by Michael Lerner, Herschel Weinstein, and Park Bramhall, and also included Lowell A. Citron, Marc Kurzweil, Brian A. Silikovitz, Christina Iafe, Jack D. Sidorov, Jeffrey M. Shapiro, Hilla Shimshoni, Tara P. D'Orsi, Michael Amalfe, Sarah Saladini and Eugene Cheval. , April 24, 2015
Lowenstein Sandler represented Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, in connection with its licensing of a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen (NASDAQ:AMGN). Financial terms of the agreements were not disclosed. Celimmune plans to initiate Phase 2 studies of AMG 714 for the treatment of diet non-responsive celiac disease and refractory celiac disease (RCD). Celiac disease is a chronic hereditary systemic autoimmune and inflammatory disease triggered by gluten consumption. The Lowenstein team included Michael J. Lerner, Herschel Weinstein, Park S. Bramhall, Brian A. Silikovitz and Lesley P. Adamo. , March 2, 2015

Related Areas

Capital Markets & Securities
Corporate
Life Sciences
Mergers & Acquisitions
Private Equity
Securities Offerings

Education


New York University School of Law ( J.D. , 2005 ) , Order of the Coif, magna cum laude
Princeton University: Woodrow Wilson School of Public and International Affairs ( M.P.A. , 1999 )
Macalester College ( B.A. , 1992 ) , summa cum laude

Bar Admissions


New York